On Jan. 4, 2021, a COVID-19 vaccine developed by AstraZeneca and Oxford University was administered for the first time, to an ...

AstraZeneca notes baxdrostat shows reduction in systolic blood pressure in phase III of uncontrolled or resistant hypertension: Our Bureau, Bengaluru Monday, January 5, 2026, 18:0 ...

Pharma giant AstraZeneca has expanded its supply deal with Michigan-based medical radioisotope producer Niowave, establishing ...

The data presented covered everything from its mainstay acalabrutinib, sold as Calquence, to the eye-catching AZD0120, an ...

AstraZeneca will end U.S. commercial sales of Andexxa Dec. 22, citing safety concerns raised in postmarketing data and a recent trial, according to a ...

AstraZeneca said on Monday that a late‑stage trial testing its blockbuster therapy Imfinzi in combination with its ...

AstraZeneca’s investigational ATR kinase inhibitor did not improve overall survival when combined with Imfinzi in patients with non-small cell lung cancer during a Phase III clinical trial, the ...

AstraZeneca has delivered on CEO Pascal Soriot’s promise to grow revenues to more than $40 billion by 2023. Now, the chief exec is already mapping out his next goal. AZ’s global revenue in 2022 ...

While AstraZeneca has announced that it will participate in the 2026 JP Morgan Healthcare Conference, it hasn’t yet revealed details about its presentation.

AstraZeneca may be emphasizing the potential for combination treatments to help its obesity pipeline stand out from the crowd, but the Big Pharma insists it is still “playing to win” in the space. The ...

Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will enter ...

On Jan. 4, 2021, a COVID-19 vaccine developed by AstraZeneca and Oxford University was administered for the first time, to an ...